The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Jan 8 (Reuters) - Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Investors poured into a room at #JPM26 to see how Revolution Medicines' CEO would dance around questions they knew he ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Merck agreed to acquire Cidara Therapeutics, a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug ...

Merck broke ground on a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Del., the Rahway-based company announced April 29. The Merck Wilmington Biotech ...

NEW YORK/FRANKFURT (Reuters) - Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

(Bloomberg) -- Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its ...